Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)
Study sponsor: Scynexis, Inc. · SCYX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-04-14Actual
Enrollment · participants30Actual
Source updated2024-07-03Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.